A Política Externa Independente em ação: a Conferência de Punta del Este de 1962 Independent Foreign Politics in action: an Overview of the Punta del Este Convention in 1962

Considerada por San Tiago Dantas como "uma reunião que marcou época na formação do americanismo", a Conferência de Punta del Este, de janeiro de 1962, dedicou-se a tratar dos efeitos da Revolução Cubana no hemisfério. Declarou-se a incompatibilidade do comunismo com os princípios americanos e suspendeu-se Cuba da Junta Interamericana de Defesa (JID) e da OEA. A participação brasileira teve grande destaque e repercussão tanto interna quanto internacionalmente. Procura-se analisar as razões que levaram o Brasil a adotar a posição de condenar o comunismo cubano e aprovar a suspensão de Cuba da JID, sem, porém, concordar com sua suspensão da OEA.<br>Considered by San Tiago Dantas as "a landmark meeting for the formation of Americanism", the Conference of Punta del Este of January 1962 dealt with the effects of the Cuban Revolution on the Hemisphere. A resolution was approved declaring the incompatibility of communism with American principles, suspended Cuba from the Inter-American Defense Board (IDB) and from the Organization of American States (OAS). The Brazilian participation gained high distinction and had repercussions not only domestically but also internationally. The present work seeks to analyse the reasons that led Brazil to condemn communism in Cuba and approve the suspension of this country from the IDB, without, however, agreeing to the suspension of Cuba from the OAS

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events